3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid {2-methyl-3-[1-methyl-5-(3-methyl-ureido)-6-oxo-1,6-dihydro-pyridin-3-yl]-phenyl}-amide | 1147529-91-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-5'-carboxylic acid {2-methyl-3-[1-methyl-5-(3-methyl-ureido)-6-oxo-1,6-dihydro-pyridin-3-yl]-phenyl}-amide
• 英文别名: N-[2-methyl-3-[1-methyl-5-(methylcarbamoylamino)-6-oxopyridin-3-yl]phenyl]-6-piperidin-1-ylpyridine-3-carboxamide
• CAS: 1147529-91-6
• 化学式: C₂₆H₃₀N₆O₃
• 分子量: 474.563
• InChiKey: DESBZSDOABFJPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  107
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• BTK protein kinase inhibitors
  申请人：Dewdney Nolan James

  公开号：US20090105209A1

  公开（公告）日：2009-04-23

  This application discloses pyridine and pyrimidine compounds according to formula I wherein R 1 , R 2 , R 3 , R 4 , R 5 , X 1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.

  这个申请公开了根据公式I的吡啶和嘧啶化合物，其中R1、R2、R3、R4、R5、X1和A如本文所述，可抑制Btk。所公开的化合物有助于调节Btk的活性，并治疗与Btk活性过度相关的疾病。这些化合物进一步用于治疗与异常B细胞增殖相关的炎症和自身免疫疾病，如类风湿性关节炎。还公开了包含公式I化合物和至少一种载体、稀释剂或助剂的组合物。
• NOVEL KINASE INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2426109A1

  公开（公告）日：2012-03-07

  Pyridine and pyrimidine compounds according to formula I wherein R1, R2, R3, R4, R5, X1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.

  符合式 I 的吡啶和嘧啶化合物 其中 R1、R2、R3、R4、R5、X1 和 A 如本文所述，可抑制 Btk。本文公开的化合物可用于调节 Btk 的活性和治疗与 Btk 活性过高有关的疾病。这些化合物还可用于治疗与 B 细胞异常增殖有关的炎症和自身免疫疾病，如类风湿性关节炎。还公开了含有式 I 化合物和至少一种载体、稀释剂或赋形剂的组合物。
• US7943618B2
  申请人：——

  公开号：US7943618B2

  公开（公告）日：2011-05-17